Materiały źródłowe

• #1 < ?php wp_title( '|', true, 'right' ); ?>

  https://surgicalneurologyint.com/surgicalint-articles/meningioma-recurrence-time-for-an-online-prediction-tool/

  Meningioma, the most common brain tumor, traditionally considered benign, has a relatively high risk of recurrence over a patients lifespan. […] Our scoping review reveals a large body of meningioma literature that has evaluated the determinants for recurrence and aggressive tumor biology, including older age, female sex, genetic abnormalities such as telomerase reverse transcriptase promoter mutation, CDKN2A deletion, subtotal resection, and higher grade. […] Although the WHO grading scale is the current standard of care informing meningioma treatment strategies, it is important to note that approximately 30% of grade 1 and 50% of grade 2 tumors recur, suggesting that some tumors are biologically different and more aggressive compared to other tumors. […] Improving risk stratification and predicting meningioma recurrence is critical for tailoring subsequent management and surveillance strategies.

• #2 Classification of meningiomas—advances and controversies – Harter – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/15104/html

  Meningiomas are the most frequent primary central nervous system (CNS) tumors. Although approximately 80% of the tumors are slow growing and benign, some subtypes are associated with a less favorable outcome. An adequate classification system aims at providing a tool for estimating recurrence and overall survival of meningioma patients. […] The extent of resection, reflected by the Simpson grade is a strong predictor of tumor recurrence. Nevertheless, in a study by Jskelinen up to 20% of benign gross-totally resected meningiomas recurred within 20 years. […] An adequate classification system basically aims at providing a tool for estimating the risk of tumor recurrence and estimating the overall survival of a patient. […] WHO grade and extent of resection are still the most important predictors of progression-free survival (PFS) and should therefore be reported for every individual patient.

• #3 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  The following are the five-year survival rates for meningioma according to the latest numbers: Grade I: 95.7%, Grade II: 81.8%, Grade III: 46.7%. Still, it’s important to remember that these survival rates are general estimates and can vary depending on individual circumstances. However, they can provide a broad understanding of the expected outcomes based on large groups of patients. […] Surgical removal of meningiomas is often the primary treatment approach, particularly for grade I and selected grade II tumors. Surgery is associated with better results and higher long-term survival rates. Still, the feasibility of complete removal depends on factors such as tumor location, size and involvement of critical structures. […] Radiation therapy is commonly used as a supportive treatment after surgery or as a primary treatment for inoperable or recurrent meningiomas. It helps control tumor growth, reduce recurrence risk and improve long-term outcomes. […] In some cases, particularly for small, asymptomatic meningiomas with a low risk of growth or symptoms, a „watchful waiting” approach is typically adopted. Regular monitoring through imaging studies allows healthcare professionals to track tumor growth and intervene if necessary.

• #4 < ?php wp_title( '|', true, 'right' ); ?>

  https://surgicalneurologyint.com/surgicalint-articles/meningioma-recurrence-time-for-an-online-prediction-tool/

  The relationship between sex and the risk of meningioma recurrence remains controversial. […] Meningioma recurrence is higher among patients with lower KPS scores. […] A recent study compared 25 patients with invasive otherwise benign meningioma and 40 brain-invasive atypical meningioma. The authors found that brain invasion was an independent prognostic factor for progression-free survival. […] In general, the Ki-67/MIB-1 proliferation index increases in proportion with the WHO grading of meningioma, which is used as an adjunct to the WHO criteria and is considered as a surrogate marker for recurrence. […] The current understanding of molecular genomics of meningiomas has rapidly evolved to elucidate major genetic and epigenetic alterations that drive clinical behavior. […] With this study, we propose the need for an online recurrence risk prediction tool because accurate prediction of meningioma recurrence following surgery is a critical part of the decision-making process to determine the need for adjuvant therapy and the appropriate surveillance strategies. […] The model would be built to assign a certain weightage to these characteristics and then identify the risk probability.

• #5 A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10646388/

  The selection of patients for further therapy after meningioma surgery remains a challenge. […] The aim of this study was to create a preselection tool warranting further molecular work-up. […] Recurrence-free survival was significantly decreased in patients in intermediate and high-risk score groups (p-value 0.001). […] The proposed prediction model showed good discrimination and calibration. […] This prediction model is based on easily obtainable information and can be used as an adjunct for patient selection for further molecular work-up in a tertiary hospital setting. […] Recurrence prediction after meningioma surgery is feasible with few parameters. […] Our model identifies tumors requiring further molecular work-up. […] It is therefore crucial to properly identify susceptible patients for P/R who are likely to benefit from additional treatment.

• #6 Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma | Nature Medicine

  https://www.nature.com/articles/s41591-024-03167-4

  Treatment of the tumor and dural margin with surgery and sometimes radiation are cornerstones of therapy for meningioma. […] Using propensity score matching, we found that gross tumor resection was associated with longer progression-free survival (PFS) across all molecular groups and longer overall survival in proliferative meningiomas. […] Dural margin treatment (Simpson grade 1/2) prolonged PFS compared to no treatment (Simpson grade 3). […] Molecular group classification predicted response to radiotherapy, including in the RTOG-0539 cohort. […] This study highlights the potential for molecular profiling to refine surgical and radiotherapy decision-making. […] Although several new molecular classifications and prognostic systems have been described for meningiomas, response to surgery and RT continues to vary considerably among patients, and the role of treatment in the context of these molecular biomarkers has not been fully explored.

• #7 Classification of meningiomas—advances and controversies – Harter – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/15104/html

  Meningiomas are the most frequent primary central nervous system (CNS) tumors. Although approximately 80% of the tumors are slow growing and benign, some subtypes are associated with a less favorable outcome. An adequate classification system aims at providing a tool for estimating recurrence and overall survival of meningioma patients. […] The extent of resection, reflected by the Simpson grade is a strong predictor of tumor recurrence. Nevertheless, in a study by Jskelinen up to 20% of benign gross-totally resected meningiomas recurred within 20 years. […] An adequate classification system basically aims at providing a tool for estimating the risk of tumor recurrence and estimating the overall survival of a patient. […] WHO grade and extent of resection are still the most important predictors of progression-free survival (PFS) and should therefore be reported for every individual patient.

• #8 Long-term follow-up in high-grade meningioma and outcome analysis – Journal of Neurosciences in Rural Practice

  https://ruralneuropractice.com/long-term-follow-up-in-high-grade-meningioma-and-outcome-analysis/

  The determinants of progression-free survival (PFS) and overall survival (OS) for higher-grade meningiomas have not been clearly established and to summarize the long-term clinical outcome for patients with grade 2 or 3 meningioma and assess the PFS and OS factors. […] The WHO grade of the tumor, the extent of resection, and the absence of bone involvement were all independent predictors of better survival in a multivariate analysis. […] The degree of tumor excision is the strongest predictor of PFS and OS. […] The PFS for these high-grade meningiomas were 95% at the end of one year, 52% at five years, and 27.5% at 10 years. […] The OS rate at 5 years, 10 years, and 15 years were 91.3%, 81.9%, and 78.4%, respectively. […] This study emphasizes that in individuals with high-grade meningiomas, the extent of excision of the tumor is the primary indicator of favorable prognosis, both in terms of PFS and OS. […] The histopathological grade, scope of the resection, and bone involvement were all found to be independent predictors of survival by the multivariate analysis.

• #9 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  Meningiomas are typically classified into three grades based on their histological characteristics and aggressiveness: grade I (benign), grade II (atypical) and grade III (anaplastic or malignant). These grades are crucial factors in determining the prognosis. […] Grade I meningiomas are the most common and least aggressive type, as they tend to have well-defined borders and grow slowly. The prognosis for grade I meningiomas is generally favorable, with a high likelihood of complete surgical removal and a low risk of recurrence. Most patients with this tumor can expect an excellent long-term prognosis, although regular monitoring may still be required. […] Grade II meningiomas are considered intermediate in terms of their aggressiveness. They may exhibit more rapid growth and have an increased risk of recurrence compared to grade I tumors. The prognosis for this type is generally less favorable, and masses can be more challenging to remove surgically. […] Grade III meningiomas are the most aggressive and least common form. They are more likely to invade surrounding tissues and spread to other parts of the central nervous system. The prognosis for grade III tumors is generally poor, as they are associated with a high risk of recurrence and have a more limited response to available treatment options.

• #10 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  Meningiomas are typically classified into three grades based on their histological characteristics and aggressiveness: grade I (benign), grade II (atypical) and grade III (anaplastic or malignant). These grades are crucial factors in determining the prognosis. […] Grade I meningiomas are the most common and least aggressive type, as they tend to have well-defined borders and grow slowly. The prognosis for grade I meningiomas is generally favorable, with a high likelihood of complete surgical removal and a low risk of recurrence. Most patients with this tumor can expect an excellent long-term prognosis, although regular monitoring may still be required. […] Grade II meningiomas are considered intermediate in terms of their aggressiveness. They may exhibit more rapid growth and have an increased risk of recurrence compared to grade I tumors. The prognosis for this type is generally less favorable, and masses can be more challenging to remove surgically. […] Grade III meningiomas are the most aggressive and least common form. They are more likely to invade surrounding tissues and spread to other parts of the central nervous system. The prognosis for grade III tumors is generally poor, as they are associated with a high risk of recurrence and have a more limited response to available treatment options.

• #11 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  Meningiomas are typically classified into three grades based on their histological characteristics and aggressiveness: grade I (benign), grade II (atypical) and grade III (anaplastic or malignant). These grades are crucial factors in determining the prognosis. […] Grade I meningiomas are the most common and least aggressive type, as they tend to have well-defined borders and grow slowly. The prognosis for grade I meningiomas is generally favorable, with a high likelihood of complete surgical removal and a low risk of recurrence. Most patients with this tumor can expect an excellent long-term prognosis, although regular monitoring may still be required. […] Grade II meningiomas are considered intermediate in terms of their aggressiveness. They may exhibit more rapid growth and have an increased risk of recurrence compared to grade I tumors. The prognosis for this type is generally less favorable, and masses can be more challenging to remove surgically. […] Grade III meningiomas are the most aggressive and least common form. They are more likely to invade surrounding tissues and spread to other parts of the central nervous system. The prognosis for grade III tumors is generally poor, as they are associated with a high risk of recurrence and have a more limited response to available treatment options.

• #12 Classification of meningiomas—advances and controversies – Harter – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/15104/html

  However, for some patients WHO grading seems insufficient as (I) almost 20% of benign WHO grade I tumors tend to recur and (II) adjuvant radiotherapy might not be necessary for all WHO grade II meningiomas. […] The application of a proliferation index for risk stratification in meningioma patients is by far not a new notion, as already former WHO classifications refer to the importance of the proliferation index when stratifying the risk of meningioma recurrence. […] A mitotic index which includes assessment of mitoses with the help of pHH3-staining is an independent predictor of meningioma recurrence. […] The last years were characterized by enormous progress on genetic understanding of meningioma genesis especially of benign meningiomas. […] Most interestingly, the analysis of TERT-promoter mutation is a strong prognosticator for meningioma patients risk stratification and is associated with rapid recurrence also in case of otherwise benign histology.

• #13 A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10646388/

  The predictive ability of genetic alterations in meningioma is deemed high, but their integration into the WHO classification remains to be established. […] By considering clinical, radiological, and histological as well as immunohistochemical parameters an accurate, well calibrated prediction model with good discrimination was created based on the variables: previous surgery, Simpson grade, progesterone receptor staining as well as presence of necrosis and patternless growth. […] These easy-to-obtain and cost-friendly variables potentially may guide selection for further molecular diagnostics and support clinical decision making.

• #14 Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11101050/

  Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. […] As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). […] In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

• #15 Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0303337

  Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. […] As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). Additionally, high expression of Ki-67 was identified as a prognosis biomarker for poor PFS of meningioma patients (HR = 1.02, 95%CI 1.00 to 1.04). […] In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

• #16 Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11101050/

  Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. […] As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). […] In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

• #17 Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0303337

  Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. […] As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). Additionally, high expression of Ki-67 was identified as a prognosis biomarker for poor PFS of meningioma patients (HR = 1.02, 95%CI 1.00 to 1.04). […] In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

• #18 Classification of meningiomas—advances and controversies – Harter – Chinese Clinical Oncology

  https://cco.amegroups.org/article/view/15104/html

  However, for some patients WHO grading seems insufficient as (I) almost 20% of benign WHO grade I tumors tend to recur and (II) adjuvant radiotherapy might not be necessary for all WHO grade II meningiomas. […] The application of a proliferation index for risk stratification in meningioma patients is by far not a new notion, as already former WHO classifications refer to the importance of the proliferation index when stratifying the risk of meningioma recurrence. […] A mitotic index which includes assessment of mitoses with the help of pHH3-staining is an independent predictor of meningioma recurrence. […] The last years were characterized by enormous progress on genetic understanding of meningioma genesis especially of benign meningiomas. […] Most interestingly, the analysis of TERT-promoter mutation is a strong prognosticator for meningioma patients risk stratification and is associated with rapid recurrence also in case of otherwise benign histology.

• #19 Neurofibromatosis type II – Wikipedia

  https://en.wikipedia.org/wiki/Neurofibromatosis_type_II

  NF2 is a life limiting condition. It is a rare genetic disorder that involves noncancerous tumors of the nerves that transmit balance and sound impulses from the inner ear to the brain. The prognosis is affected by early age onset, a higher number of meningiomas and schwannomas and having a decrease in mutation. […] An early diagnosis is the best way to ensure improvement in management. Although, even with an early diagnosis, some patients still die very young. […] Meningiomas and schwannomas occur in around half of patients with NF2. Meningiomas are tumors that are both intracranial and intraspinal. Schwannomas are tumors that are often centered on the internal auditory canal. Patients with NF2 who have meningiomas have a higher risk of mortality, and the treatment can be very challenging. […] Truncating mutations lead to smaller and non-functional protein products. Studies have shown that missense mutations and large deletions can both cause predominantly mild phenotypes. […] Patients with a missense mutation have a greater survival rate than nonsense and frameshift mutations.

• #20

  https://link.springer.com/article/10.1007/s10143-023-02004-5

  Despite the importance of functional outcome, only a few scoring systems exist to predict neurologic outcome in meningioma surgery. […] Our study aims to identify preoperative risk factors and develop the receiver operating characteristics (ROC) models estimating the risk of a new postoperative neurologic deficit and a decrease in Karnofsky performance status (KPS). […] A ROC model was developed to estimate the probability of a new neurologic deficit (area 0.74; SE 0.0284; 95% Wald confidence limits (0.69; 0.80)) based on meningioma location and diameter. […] Consequently, a ROC model was developed to predict the probability of a postoperative decrease in KPS (area 0.80; SE 0.0289; 95% Wald confidence limits (0.74; 0.85)) based on the patients age, meningioma location, diameter, presence of hyperostosis, and dural tail.

• #21 Role of risk factors, scoring systems, and prognostic models in predicting the functional outcome in meningioma surgery…

  https://ouci.dntb.gov.ua/en/works/9JWORqA7/

  Despite the importance of functional outcome, only a few scoring systems exist to predict neurologic outcome in meningioma surgery. […] A ROC model was developed to estimate the probability of a new neurologic deficit (area 0.74; SE 0.0284; 95% Wald confidence limits (0.69; 0.80)) based on meningioma location and diameter. […] Consequently, a ROC model was developed to predict the probability of a postoperative decrease in KPS (area 0.80; SE 0.0289; 95% Wald confidence limits (0.74; 0.85)) based on the patient’s age, meningioma location, diameter, presence of hyperostosis, and dural tail. […] To ensure an evidence-based therapeutic approach, treatment should be founded on known risk factors, scoring systems, and predictive models. […] We propose ROC models predicting the functional outcome of skull base meningioma resection based on the age of the patient, meningioma size, and location and the presence of hyperostosis and dural tail.

• #22

  https://link.springer.com/article/10.1007/s10143-023-02004-5

  To ensure an evidence-based therapeutic approach, treatment should be founded on known risk factors, scoring systems, and predictive models. […] We propose ROC models predicting the functional outcome of skull base meningioma resection based on the age of the patient, meningioma size, and location and the presence of hyperostosis and dural tail. […] The predictive factors of a new neurologic deficit (temporary or permanent, evaluated at 1 year from surgical resection) and a decrease in KPS (at patient discharge) selected by the multivariate stepwise selection model are presented in Table 5. […] According to univariate analysis (done by the logistic regression univariate model), the risk factors associated with higher probability of a new neurologic deficit were the following: presence of major vessel contact, higher diameter, higher volume, supratentorial location, presence of cavernous sinus invasion, presence of vessel narrowing, and presence of edema.

• #23

  https://link.springer.com/article/10.1007/s10143-023-02004-5

  In multivariate analysis (done by the multivariate stepwise selection logistic regression model), higher diameter (p = 0.0043) and higher volume (p = 0.0406) were associated with higher probability of a new neurologic deficit. […] According to univariate analysis (done by the logistic regression univariate model), factors associated with higher probability of a decrease in KPS at patient discharge were higher diameter, higher volume, presence of edema, infratentorial location, higher age, major artery contact, and lower GCS. […] Factors associated with higher probability of a decrease in KPS in multivariate analysis (done by the multivariate stepwise selection logistic regression model) were higher diameter (p 0.0001), higher volume (p = 0.0909), higher patient age (p = 0.0213), and presence of dural tail (p = 0.0411). […] An evidence-based therapeutic approach should be based on known risk factors, scoring systems, and predictive models.

• #24

  https://link.springer.com/article/10.1007/s10143-023-02004-5

  Despite the importance of functional outcome, only a few scoring systems exist to predict neurologic outcome in meningioma surgery. […] Our study aims to identify preoperative risk factors and develop the receiver operating characteristics (ROC) models estimating the risk of a new postoperative neurologic deficit and a decrease in Karnofsky performance status (KPS). […] A ROC model was developed to estimate the probability of a new neurologic deficit (area 0.74; SE 0.0284; 95% Wald confidence limits (0.69; 0.80)) based on meningioma location and diameter. […] Consequently, a ROC model was developed to predict the probability of a postoperative decrease in KPS (area 0.80; SE 0.0289; 95% Wald confidence limits (0.74; 0.85)) based on the patients age, meningioma location, diameter, presence of hyperostosis, and dural tail.

• #25 Role of risk factors, scoring systems, and prognostic models in predicting the functional outcome in meningioma surgery…

  https://ouci.dntb.gov.ua/en/works/9JWORqA7/

  Despite the importance of functional outcome, only a few scoring systems exist to predict neurologic outcome in meningioma surgery. […] A ROC model was developed to estimate the probability of a new neurologic deficit (area 0.74; SE 0.0284; 95% Wald confidence limits (0.69; 0.80)) based on meningioma location and diameter. […] Consequently, a ROC model was developed to predict the probability of a postoperative decrease in KPS (area 0.80; SE 0.0289; 95% Wald confidence limits (0.74; 0.85)) based on the patient’s age, meningioma location, diameter, presence of hyperostosis, and dural tail. […] To ensure an evidence-based therapeutic approach, treatment should be founded on known risk factors, scoring systems, and predictive models. […] We propose ROC models predicting the functional outcome of skull base meningioma resection based on the age of the patient, meningioma size, and location and the presence of hyperostosis and dural tail.

• #26 A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10646388/

  The selection of patients for further therapy after meningioma surgery remains a challenge. […] The aim of this study was to create a preselection tool warranting further molecular work-up. […] Recurrence-free survival was significantly decreased in patients in intermediate and high-risk score groups (p-value 0.001). […] The proposed prediction model showed good discrimination and calibration. […] This prediction model is based on easily obtainable information and can be used as an adjunct for patient selection for further molecular work-up in a tertiary hospital setting. […] Recurrence prediction after meningioma surgery is feasible with few parameters. […] Our model identifies tumors requiring further molecular work-up. […] It is therefore crucial to properly identify susceptible patients for P/R who are likely to benefit from additional treatment.

• #27 A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10646388/

  The predictive ability of genetic alterations in meningioma is deemed high, but their integration into the WHO classification remains to be established. […] By considering clinical, radiological, and histological as well as immunohistochemical parameters an accurate, well calibrated prediction model with good discrimination was created based on the variables: previous surgery, Simpson grade, progesterone receptor staining as well as presence of necrosis and patternless growth. […] These easy-to-obtain and cost-friendly variables potentially may guide selection for further molecular diagnostics and support clinical decision making.

• #28

  https://link.springer.com/article/10.1007/s00701-023-05831-z

  Atypical meningioma (AM) recurs in up to half of patients after surgical resection and may require adjuvant therapy to improve patient prognosis. […] Thus, in this study, we aimed to develop and validate an integrated prognostic model for AM. […] The random survival forest (RSF) model was the best model for predicting recurrence and death. […] A high-performing integrated RSF predictive model for AM recurrence and patient mortality was proposed that may guide therapeutic decision-making and long-term monitoring.

• #29 Preoperative prediction of CNS WHO grade and tumour aggressiveness in intracranial meningioma based on radiomics and structured semantics | Scientific Reports

  https://www.nature.com/articles/s41598-024-71200-0

  Preoperative determination of aggressiveness based on diagnostic imaging would provide an attractive opportunity to adjust the treatment strategy, for example opting for watch and wait in the case of non-aggressive meningiomas or for aggressive resection followed by adjuvant radiotherapy in the case of aggressive tumours.

• #30 Preoperative prediction of CNS WHO grade and tumour aggressiveness in intracranial meningioma based on radiomics and structured semantics | Scientific Reports

  https://www.nature.com/articles/s41598-024-71200-0

  Preoperative identification of intracranial meningiomas with aggressive behaviour may help in choosing the optimal treatment strategy. […] Radiomic analysis is a promising tool for preoperative identification of aggressive and atypical intracranial meningiomas and could become a useful tool in the future. […] The best models in each category were also combined with human classifiers (radiological analysis) and semantic analysis and evaluated in the respective test sets. The combination of radiologists opinion to the radiomics model did not markedly increase the models performance to predict CNS WHO grade 2 and it even decreased for predicting early recurrence. […] This study demonstrates that the radiomic analysis can be applied to determine tumour aggressiveness and CNS WHO grade. This approach was superior in comparison to experienced neuroradiologists and morphological analysis in terms of the proposed semantic feature score.

• #31 Quality of Life in Patients with Meningioma | IntechOpen

  https://www.intechopen.com/chapters/1157417

  Meningiomas are common benign brain tumors that may significantly impact patients Health-Related Quality of Life (HRQOL) and functional disability. […] Although patients generally experience improved HRQOL post-surgery, some may face long-term declines, necessitating comprehensive long-term well-being evaluation. […] Long-term outcomes highlight meningiomas chronic impact on patients lives and socioeconomic burden. […] Overall, understanding and addressing these factors optimizes patients well-being and functional outcomes. […] Advancements in radiation and surgical techniques have remarkably improved the prognosis for patients diagnosed with meningiomas. […] However, patient functionality is inevitably impacted by the physical and cognitive symptoms associated with meningiomas, leading to inherent limitations in their daily lives, which substantially reduce their life quality.

• #32 Quality of Life in Patients with Meningioma | IntechOpen

  https://www.intechopen.com/chapters/1157417

  The long-term burden of meningioma has been determined by clinical risk factors including treatment characteristics and complications like surgery-related complications, reoperation, and radiotherapy, as well as tumor characteristics. […] Remarkably, the study demonstrated that 67% of meningioma patients suffered from neurocognitive deficits, which negatively impacted their HRQoL. […] In light of these findings, healthcare providers should place particular emphasis on these clinical risk factors when gathering patient history. […] Predominant non-clinical predictors often encompass sociodemographic variables, including age, gender, household income, socioeconomic status, insurance coverage, and marital status. […] It is interesting to note that in the long-time monitoring of patients with meningioma, HRQoL outcomes of different studies have yielded conflicting findings with different risk factors.

• #33 Quality of Life in Patients with Meningioma | IntechOpen

  https://www.intechopen.com/chapters/1157417

  Patients might undergo a positive mental transformation, known as posttraumatic growth, which is commonly observed in long-term follow-up of patients with various types of cancer or acquired brain injury. […] Symptomatic meningiomas suffer from a wide range of clinical severity and symptoms, largely dependent on their specific location within the brain. […] Furthermore, in meningioma patients, prevalent preoperative symptoms include alterations in vision, cranial nerve impairments, ambulation challenges, cognitive deterioration, and tinnitus. […] It is worth noting that HRQoL scores were positively associated with optic nerve decompression and the absence of proptosis. […] While neurocognitive impairments can endure in meningioma patients post-treatment, the majority of patients tend to see an enhancement in their HRQoL after surgery.

• #34 Quality of Life in Patients with Meningioma | IntechOpen

  https://www.intechopen.com/chapters/1157417

  However, some patients may experience a long-term decline in HRQoL, particularly in areas related to social and emotional functioning. […] To be more specific, various factors contributing to postoperative quality of life are as follows: burden of symptoms, age, size of tumor, histological grade, and extent of resection in surgery. […] Meningioma patients usually go through a positive clinical progression, where the treatment intensity is moderate and mainly involves neurosurgery. […] Despite potential short-term setbacks in verbal memory, working memory, and executive function, there have been observations of sustained or even enhanced HRQoL in the long run after skull-base meningioma removal and radiotherapy. […] In the long run, patients may consistently report ongoing reduction in HRQoL, particularly in the areas of social, emotional, cognitive, and executive functioning, even more than 120 months after their surgical treatment. […] Overall, enhancing HRQoL outcomes for meningioma patients requires a comprehensive approach that addresses both medical and psychosocial factors derived from the tumor and focuses on interactive communication for effective monitoring of their HRQoL.

• #35 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  The following are the five-year survival rates for meningioma according to the latest numbers: Grade I: 95.7%, Grade II: 81.8%, Grade III: 46.7%. Still, it’s important to remember that these survival rates are general estimates and can vary depending on individual circumstances. However, they can provide a broad understanding of the expected outcomes based on large groups of patients. […] Surgical removal of meningiomas is often the primary treatment approach, particularly for grade I and selected grade II tumors. Surgery is associated with better results and higher long-term survival rates. Still, the feasibility of complete removal depends on factors such as tumor location, size and involvement of critical structures. […] Radiation therapy is commonly used as a supportive treatment after surgery or as a primary treatment for inoperable or recurrent meningiomas. It helps control tumor growth, reduce recurrence risk and improve long-term outcomes. […] In some cases, particularly for small, asymptomatic meningiomas with a low risk of growth or symptoms, a „watchful waiting” approach is typically adopted. Regular monitoring through imaging studies allows healthcare professionals to track tumor growth and intervene if necessary.

• #36 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  The following are the five-year survival rates for meningioma according to the latest numbers: Grade I: 95.7%, Grade II: 81.8%, Grade III: 46.7%. Still, it’s important to remember that these survival rates are general estimates and can vary depending on individual circumstances. However, they can provide a broad understanding of the expected outcomes based on large groups of patients. […] Surgical removal of meningiomas is often the primary treatment approach, particularly for grade I and selected grade II tumors. Surgery is associated with better results and higher long-term survival rates. Still, the feasibility of complete removal depends on factors such as tumor location, size and involvement of critical structures. […] Radiation therapy is commonly used as a supportive treatment after surgery or as a primary treatment for inoperable or recurrent meningiomas. It helps control tumor growth, reduce recurrence risk and improve long-term outcomes. […] In some cases, particularly for small, asymptomatic meningiomas with a low risk of growth or symptoms, a „watchful waiting” approach is typically adopted. Regular monitoring through imaging studies allows healthcare professionals to track tumor growth and intervene if necessary.

• #37 Meningioma Outlook and Prognosis | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/meningioma/survival/outlook-and-prognosis

  The following are the five-year survival rates for meningioma according to the latest numbers: Grade I: 95.7%, Grade II: 81.8%, Grade III: 46.7%. Still, it’s important to remember that these survival rates are general estimates and can vary depending on individual circumstances. However, they can provide a broad understanding of the expected outcomes based on large groups of patients. […] Surgical removal of meningiomas is often the primary treatment approach, particularly for grade I and selected grade II tumors. Surgery is associated with better results and higher long-term survival rates. Still, the feasibility of complete removal depends on factors such as tumor location, size and involvement of critical structures. […] Radiation therapy is commonly used as a supportive treatment after surgery or as a primary treatment for inoperable or recurrent meningiomas. It helps control tumor growth, reduce recurrence risk and improve long-term outcomes. […] In some cases, particularly for small, asymptomatic meningiomas with a low risk of growth or symptoms, a „watchful waiting” approach is typically adopted. Regular monitoring through imaging studies allows healthcare professionals to track tumor growth and intervene if necessary.

• #38 Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma | Nature Medicine

  https://www.nature.com/articles/s41591-024-03167-4

  Treatment of the tumor and dural margin with surgery and sometimes radiation are cornerstones of therapy for meningioma. […] Using propensity score matching, we found that gross tumor resection was associated with longer progression-free survival (PFS) across all molecular groups and longer overall survival in proliferative meningiomas. […] Dural margin treatment (Simpson grade 1/2) prolonged PFS compared to no treatment (Simpson grade 3). […] Molecular group classification predicted response to radiotherapy, including in the RTOG-0539 cohort. […] This study highlights the potential for molecular profiling to refine surgical and radiotherapy decision-making. […] Although several new molecular classifications and prognostic systems have been described for meningiomas, response to surgery and RT continues to vary considerably among patients, and the role of treatment in the context of these molecular biomarkers has not been fully explored.

• #39 Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma | Nature Medicine

  https://www.nature.com/articles/s41591-024-03167-4

  Our results show that GTR imparts favorable PFS across all Molecular Groups compared to STR and although the benefits of GTR are less durable with respect to local control in more biologically aggressive meningiomas, complete resection does confer an OS benefit for these molecularly defined Proliferative meningiomas. […] These findings support the rationale for investigating RT results for meningiomas in the context of molecular classification and considering future molecular-pathology informed clinical trials to investigate systemic treatments for RT-resistant meningiomas.

• #40 Meningioma Prognosis | Brain Tumour Survival Rates

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/meningioma/meningioma-prognosis/

  Meningioma prognosis means a doctor telling you the likely outcome of your diagnosis. This will be based on averages and depends on the grade of tumour that you have. […] Your doctor cannot be absolutely certain about what will happen to you following a diagnosis of a meningioma. They can give you an estimate, based on your diagnosis and current situation. But, there are things that they might not be able to predict, like how well you could respond to treatment. This is why meningioma prognosis is often an ongoing process and your medical team will likely revise it at different stages in your journey. […] More than 80% of people with this type of meningioma survive for 5 years or more after diagnosis. […] More than 60% of people with a high grade meningioma survive for 5 years or more after diagnosis.

• #41 Meningioma Prognosis | Brain Tumour Survival Rates

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/meningioma/meningioma-prognosis/

  It is important to remember that statistics and averages cannot tell you what will happen to you specifically. […] Different people approach their meningioma prognosis in different ways. […] Whichever reaction comes naturally to you is perfectly fine. It is entirely up to you whether or when you want to speak to your doctor about your prognosis.

Zobacz więcej